HALO

Halozyme Therapeutics Inc

Add to Watchlist

Advanced Chart

78.280

+0.47(0.604%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

79.310

Open

78.120

VWAP

78.00

Vol

1.62M

Mkt Cap

9.16B

Low

77.050

Amount

126.42M

EV/EBITDA(TTM)

13.23

Total Shares

116.97M

10.12B

EV/OCF(TTM)

18.47

P/S(TTM)

8.47

Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing solutions to improve patient experiences and outcomes for emerging and established therapies. The Company's commercially-validated solution, ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, is used to facilitate the subcutaneous delivery of injected drugs and fluids, with a focus on improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. The Company licenses its technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with its partners’ proprietary compounds. It also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and Idorsia Pharmaceuticals.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

367.50M

+38.75%

1.637

+47.45%

392.21M

+31.61%

1.855

+47.19%

339.74M

+17.12%

1.611

+26.82%

Estimates Revision

The market is revising Upward the revenue expectations for Halozyme Therapeutics, Inc. (HALO) for FY2025, with the revenue forecasts being adjusted by 6.07% over the past three months. During the same period, the stock price has changed by 48.26%.

Revenue Estimates for FY2025

Revise Upward

+6.07%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+13%

In Past 3 Month

Stock Price

Go Up

+48.26%

In Past 3 Month

8 Analyst Rating

-8.98% Downside

Wall Street analysts forecast HALO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for HALO is 71.25 USD with a low forecast of 51.00 USD and a high forecast of 91.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

2 Hold

1 Sell

Moderate Buy

-8.98% Downside

Current: 78.280

Low

51.00

Averages

71.25

High

91.00

-8.98% Downside

Current: 78.280

Low

51.00

Averages

71.25

High

91.00

H.C. Wainwright

Buy

maintain

$75 -> $85

2025-09-22

New

Reason

H.C. Wainwright

Price Target

$75 -> $85

2025-09-22

New

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Halozyme (HALO) to $85 from $75 and keeps a Buy rating on the shares. The FDA approval of Merck's (MRK) subcutaneous Keytruda across 38 tumor indications turns Halozyme's lawsuit into live multibillion dollar share catalyst, the analyst tells investors in a research note. The firm says the approval ensures that Halozyme's case is no longer about a theoretical formulation but a major commercial franchise with near-term sales relevance.

Morgan Stanley

Overweight

maintain

$75 -> $80

2025-08-18

Reason

Morgan Stanley

Price Target

$75 -> $80

2025-08-18

maintain

Overweight

Reason

Morgan Stanley raised the firm's price target on Halozyme to $80 from $75 and keeps an Overweight rating on the shares. Halozyme's 2025 EPS guidance has increased by 20% since January, driven by partnered products and cost discipline, notes the analyst, who adjusted the firm's earnings outlook to consider the higher 2025 base and its implications for future long-term earnings guidance.

Morgan Stanley

Equal Weight -> Overweight

upgrade

$62 -> $75

2025-08-06

Reason

Morgan Stanley

Price Target

$62 -> $75

2025-08-06

upgrade

Equal Weight -> Overweight

Reason

Morgan Stanley upgraded Halozyme to Overweight from Equal Weight with a price target of $75, up from $62, post the Q2 sales beat. The company upped its fiscal 2025 guidance due to strong royalty revenues, the analyst tells investors in a research note. The firm says it now has higher conviction on Halozyme's future growth trajectory and regulatory outlook.

H.C. Wainwright

Mitchell Kapoor

maintain

$72 -> $75

2025-08-06

Reason

H.C. Wainwright

Mitchell Kapoor

Price Target

$72 -> $75

2025-08-06

maintain

Reason

H.C. Wainwright analyst Mitchell Kapoor raised the firm's price target on Halozyme to $75 from $72 and keeps a Buy rating on the shares following the Q2 report. The company increased its fiscal 2025 guidance for the third time this year after reporting another robust quarter, the analyst tells investors in a research note.

Goldman Sachs

Neutral

maintain

$55

2025-07-10

Reason

Goldman Sachs

Price Target

$55

2025-07-10

maintain

Neutral

Reason

Goldman Sachs resumed coverage of Halozyme with a Neutral rating and $55 price target. The firm expects the hares to be range-bound until there is greater regulatory clarity.

Morgan Stanley

Sean Laaman

Overweight -> Equal Weight

downgrade

$73 -> $62

2025-05-14

Reason

Morgan Stanley

Sean Laaman

Price Target

$73 -> $62

2025-05-14

downgrade

Overweight -> Equal Weight

Reason

Morgan Stanley analyst Sean Laaman downgraded Halozyme to Equal Weight from Overweight with a price target of $62, down from $73. The firm says the issuance by Centers for Medicare and Medicaid Services of draft pricing guidance "creates too much uncertainty" to remain Overweight Halozyme. While any outcome could prove to be benign, and the stock price has accommodated some risk, CMS will not issue final guidance until later in 2025, the analyst tells investors in a research note. Morgan says the CMS draft may impact Halozyme's drug pricing, posing a headwind for hyaluronidase products.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Halozyme Therapeutics Inc (HALO.O) is 11.25, compared to its 5-year average forward P/E of 15.24. For a more detailed relative valuation and DCF analysis to assess Halozyme Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair

5Y Average PE

15.24

Current PE

11.25

Overvalued PE

19.93

Undervalued PE

10.55

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

14.25

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

18.53

Undervalued EV/EBITDA

9.96

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

7.91

Current PS

0.00

Overvalued PS

11.00

Undervalued PS

4.82

Financials

Annual

Quarterly

FY2025Q2

YoY :

+40.79%

325.72M

Total Revenue

FY2025Q2

YoY :

+72.68%

202.44M

Operating Profit

FY2025Q2

YoY :

+77.12%

165.16M

Net Income after Tax

FY2025Q2

YoY :

+84.72%

1.33

EPS - Diluted

FY2025Q2

YoY :

+84.45%

98.15M

Free Cash Flow

FY2025Q2

YoY :

+6.80%

80.31

Gross Profit Margin - %

FY2025Q2

YoY :

-1.90%

45.87

FCF Margin - %

FY2025Q2

YoY :

+25.83%

50.71

Net Margin - %

FY2025Q2

YoY :

+53.51%

31.47

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

13.5M

USD

3-6

Months

3.5M

USD

6-9

Months

2.3M

USD

0-12

Months

2.1M

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds areSelling! The selling amount has increased 4215.85% over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

495.5K

Volume

6-9

Months

11.5K

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

105.1K

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress areSelling! The selling amount has increased100%over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

16.0K

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

13.5M

USD

3-6

Months

3.5M

USD

6-9

Months

2.3M

USD

0-12

Months

2.1M

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

HALO News & Events

Events Timeline

2025-08-05 (ET)

2025-08-05

16:08:47

Halozyme raises FY25 non-GAAP EPS view to $6.00-$6.40 from $5.30-$5.70

2025-08-05

16:06:43

Halozyme reports Q2 non-GAAP EPS $1.54, consensus $1.23

2025-07-23 (ET)

2025-07-23

11:38:34

Halozyme says EU approves new indication for Janssen's Darzalex Faspro

News

9.0

09:00 AMNASDAQ.COM

PinnedStock of the Day: Halozyme Therapeutics (HALO)

4.0

09-22Benzinga

HC Wainwright & Co. Reaffirms Buy Rating for Halozyme Therapeutics, Increases Price Target to $85

2.0

09-19NASDAQ.COM

Halozyme Therapeutics (HALO) Sees 2.63% Increase Over the Past Week: Key Insights

People Also Watch

Bright Horizons Family Solutions Inc

Jackson Financial Inc

Clearwater Analytics Holdings Inc

Watts Water Technologies Inc

Colliers International Group Inc

FAQ

What is Halozyme Therapeutics Inc (HALO) stock price today?

The current price of HALO is 78.28 USD — it has increased 0.6 % in the last trading day.

HALO

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

HALO News & Events

Events Timeline

News

People Also Watch

FAQ

What is Halozyme Therapeutics Inc (HALO) stock price today?

What is Halozyme Therapeutics Inc (HALO)'s business?

What is the price predicton of HALO Stock?

What is Halozyme Therapeutics Inc (HALO)'s revenue for the last quarter?

What is Halozyme Therapeutics Inc (HALO)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Halozyme Therapeutics Inc (HALO)'s fundamentals?

How many employees does Halozyme Therapeutics Inc (HALO). have?

What is Halozyme Therapeutics Inc (HALO) market cap?